Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE-SSPE
NCT04263038Phase 4Recruiting
- Start
- May 2020
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 4, randomised, double-blind trial of rivaroxaban in pulmonary embolism (PE) (2 arms). Primary endpoint: Recurrent venous thromboembolism at 90 days. Started May 2020; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT04263038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04263038.